Multiple Myeloma
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification
Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the…
Date: 4th April 2024
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT
The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory…
Date: 15th March 2024
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology
While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due…
Date: 7th March 2024
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic…
Date: 18th January 2024
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP
In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in…
Date: 24th November 2023
Applications of MRD in multiple myeloma: using MRD to guide treatment decisions
Measurable residual disease (MRD) has become a key biomarker in the field of multiple myeloma (MM), and the sensitivity of…
Date: 8th September 2023
Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma
Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory…
Date: 3rd August 2023
Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team
Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage….
Date: 11th July 2023
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients…
Date: 22nd June 2023
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…
Date: 2nd May 2023
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…
Date: 19th April 2023
iwMyeloma Session I: genomics of high-risk and smoldering multiple myeloma
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…
Date: 12th April 2023
